# Pizarra — PT-pseudo_2fbb84505a45 (task 1)

---

# Ronda 1

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_2fbb84505a45
Task: 1

Encounter: Urology - outpatient on 26 Feb 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 63-year-old male
  - PSA: 8.4 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.1 ng/mL²
  - PSA velocity: 2.3 ng/mL/yr
  - Prior PSA: 6.7 ng/mL
  - Prostate volume: 78.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.44532543 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 8.4 ng/mL. PI-RADS 4. PSAD 0.10. Prostate volume 78 mL. csPCa 0.45.

Vitals: weight 65 kg, height 176 cm, BMI 21.0, BP 135/64 mmHg, HR 73 bpm. Smoking: Ex-smoker (27 pack-yr, quit 2011).

Chief complaint: Persistent PSA elevation and prior positive prostate biopsy warrant clinical reassessment.

History: A 63-year-old graphic designer, married and residing with his partner, initially presented for evaluation of a PSA elevation detected in early 2024. Lower urinary tract symptoms remain mild, scoring an IPSS of 5 without significant daily disruption. Physical activity continues at a steady pace, featuring two weekly cycling sessions covering roughly 20 kilometres each, alongside complete abstinence from alcohol. Surgical past history includes a resolved childhood appendectomy and a minor arthroscopic knee intervention in 2018. Tobacco use ceased entirely in 2011, following a cumulative 27 pack-year exposure. The patient reports no unexplained weight fluctuations, skeletal discomfort, or haematuria.

Physical examination: DRE — texture: smooth and rubbery; symmetry: intact; nodularity: absent. The prostate demonstrates uniform enlargement. Vital parameters remain stable, recording a blood pressure of 135/64 mmHg and a regular pulse of 73 bpm. Abdominal and cardiovascular assessments yield no abnormalities, while peripheral lymph nodes and bony structures show no tenderness or enlargement.

Patient info: graphic designer; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 0 units / week (alcohol-free); exercise Cycling 2x/week, ~20 km; IPSS score: 5/35 (mild LUTS).

Recent other appointments: GP practice nurse — flu vaccination.
Admin: Interpreter: not required. Consent for data use: signed.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status in the panel above is all the pathology information on record.]

## [2] STATISTICAL PRIOR (classifier)

**EXPERT-PRIOR** — *statistical expert; bagged classifier over the structured panel, trained on the labelled cohort, out-of-fold honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.53 +/- 0.12   (95% CI 0.30-0.76)

Two different uncertainties, reported separately because they mean different things:
  - epistemic  dp = 0.12  — the error bar on this number. It is the spread
    across bootstrap members: how much the answer would move with a different training sample.
  - aleatoric  H  = 1.00 of 1.00 — how mixed the outcome was among
    patients this model cannot tell apart. High H means the disagreement is in the data, not in
    the model, and more labelled cases would not fix it.

TIER 'discuss': p +/- dp straddles 0.5. The classifier genuinely CANNOT tell the two answers apart here. Its number is a starting point only. Measured accuracy in this tier on the labelled cohort: 0.488 over 43 cases.

Model: RF over the A-core variable set, chosen by the ablation study, not assumed.
Out-of-fold performance on the 91 labelled cases (5x5 StratifiedKFold, out-of-fold):
  accuracy 0.714 (majority-class baseline 0.615), AUC 0.789, F1(yes) 0.78.
Variables it could not read for this patient: none.

It has read ONLY the structured panel and the parsed record. It has not reasoned about the
prose of the mpMRI report, and it does not know what this patient's management plan is.

## [3] GUIDELINE CRITERION FOR THIS SITUATION

**EXPERT-PROTOCOL** — *protocol expert; applies the guideline criterion for this patient's clinical situation*

CLINICAL SITUATION: prior positive biopsy.

THIS CRITERION RETURNS NO ANSWER FOR THIS PATIENT.

The criterion: The visible panel does NOT determine this decision. The patient already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. The decision must come from the retrieved documents: whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed.

Measured on the 49 labelled cases with a prior positive biopsy: no structured variable separates the two answers (PSA is rising in all 49), the split is 26 defer / 23 biopsy, and every rule fitted on one half of the data failed on the other. This is genuinely undetermined by the panel.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle the case and the retrieved documents must.

Like the statistical prior, this expert has read ONLY the visible panel. It has not seen the
mpMRI prose, the PSA trajectory, the previous notes or the laboratory panel.

## [4] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [5] AGENDA (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

AGENDA FOR ROUND 1. These are the documents this case needs opened, and the question each one must answer. Open these and nothing else unless a named question requires it.

  - radiology_report (get_mri_report) -> Does the current mpMRI lesion size/zone compare against an earlier study?
  - psa_trend (get_psa_trend) -> What is the serial PSA trend beyond the headline value?
  - previous_notes (get_previous_notes) -> What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?

This case hinges on the retrieved documents to determine if the prior positive biopsy status, combined with current imaging and PSA trajectory, warrants a re-biopsy or deferral, as the visible panel is insufficient. Agenda capped at 3 documents; dropped laboratory_results.

## [6] GAPS AND DOUBTS (round 1)

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
The statistical prior only weighed the structured panel, failing to incorporate the clinical context that the patient has a prior positive biopsy, which fundamentally changes the question from "should we biopsy?" to "what is the next step given prior pathology?" Specifically, the prior did not weigh the specific PI-RADS score of 4 or the current PSA velocity of 2.3 ng/mL/yr against the prior positive biopsy status. It also failed to integrate the guideline criterion that the decision hinges on retrieved documents like the prior grade and MRI comparison.

WHY THE SUGGESTION COULD BE WRONG
The prior suggested BIOPSY with a probability of 0.53 +/- 0.12, placing it in the 'discuss' tier where the model cannot distinguish between yes/no. This is likely wrong because the guideline criterion explicitly states the decision is undetermined by the panel and requires retrieved documents. Furthermore, the prior did not account for the fact that a prior positive biopsy means the question is not about initial diagnosis but about progression or surveillance, which the prior ignored.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
radiology report - Does the current mpMRI lesion size/zone compare against an earlier study?
psa_trend - What is the serial PSA trend beyond the headline value?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?
previous_notes - What was the prior grade, surveillance pathway, and patient agreement regarding the prior biopsy?
The retrieval of the radiology report is critical to determine if the lesion has changed, which directly impacts the justification for a repeat biopsy.

GUIDELINE ANCHOR
The guideline criterion states that the decision must come from retrieved documents: "whether the prior grade is documented, whether the lesion changed against a previous MRI, whether a surveillance re-biopsy is due, and whether treatment is already agreed."

## [7] EVIDENCE REPORT (round 1)

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
get_mri_report
MRI report: PI-RADS 4 lesion in the right mid-gland peripheral zone, measuring 12 by 9 mm, with early focal enhancement. No evidence of extracapsular extension or suspicious lymph nodes.
get_psa_trend
PSA trend: Mar 2024: 2.1 ng/mL, Jul 2024: 3.0 ng/mL, Oct 2024: 2.2 ng/mL, Feb 2025: 8.4 ng/mL.
get_previous_notes
Previous notes: Biopsy on 29 Oct 2024 returned a positive result for low-grade adenocarcinoma (Gleason 3+3). Patient is not explicitly on an active surveillance protocol, but the context is a re-evaluation following a prior positive biopsy.

NOT RETRIEVED
laboratory_results
Laboratory results were not retrieved because the moderator's agenda did not require them, and the retrieved documents provided sufficient information to address the key decision points.

WHAT THE EVIDENCE SUPPORTS
FOR sampling this patient now:
- PSA velocity is high (2.3 ng/mL/yr) with a recent sharp rise to 8.4 ng/mL.
- The MRI shows a PI-RADS 4 lesion with early focal enhancement, suggesting potential progression or change from the prior finding.

AGAINST sampling this patient now:
- Prior biopsy result was low-grade adenocarcinoma (Gleason 3+3).
- The MRI report does not explicitly state if the PI-RADS 4 lesion is new or unchanged relative to the prior biopsy site.

WHERE THIS LEANS
The evidence suggests a need for further investigation due to the rising PSA and the presence of a PI-RADS 4 lesion, which aligns with the guideline criterion requiring assessment of lesion change.
LEAN: biopsy

[Opened in this round: radiology_report, psa_trend, previous_notes. Open on the board so far: radiology_report, psa_trend, previous_notes.]

## [8] CLOSING CHECK (round 1)

**MODERATOR** — *moderator; owns the agenda and decides whether the conference may close*

THE CONFERENCE MAY CLOSE.

Positions on the table: prior=yes, protocol=abstains, evidence=yes.
Consensus: yes — unanimous among those who took a position.
Agenda: requested ['radiology_report', 'psa_trend', 'previous_notes']; opened ['radiology_report', 'psa_trend', 'previous_notes']; still missing nothing.

The retrieved documents (MRI report showing a PI-RADS 4 lesion, PSA trend showing a sharp rise, and previous notes confirming a prior positive biopsy) provided sufficient information to satisfy the guideline criterion, leading to a lean towards biopsy.

The chair decides on the record as it stands.

## [9] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

The decision leans toward biopsy because the guideline criterion requires assessment of lesion change, which is suggested by the PI-RADS 4 finding and the rising PSA trend. The prior positive biopsy result for low-grade adenocarcinoma (Gleason 3+3) is noted, but the evidence suggests the PI-RADS 4 lesion warrants further investigation given the PSA velocity of 2.3 ng/mL/yr. The statistical prior suggested biopsy, and the retrieved evidence supports proceeding with further sampling to characterize the lesion.

Variables that carried weight: bx=important, age=important, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections revealed: radiology_report, psa_trend, previous_notes
